Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Studies on Pyrrolopyrimidines as Selective Inhibitors of Multidrug-Resistance- Associated Protein in Multidrug Resistance

7 Feb 2004

Abstract excerpt

Multidrug resistance mediated by P-glycoprotein (Pgp) or multidrug-resistance-associated protein (MRP) remains a major obstacle for successful treatment of cancer. Inhibition of Pgp and MRP transport is important for high efficacy of anticancer drugs. While several Pgp inhibitors have entered clinical trials, the development of specific MRP1 inhibitors is still in its infancy. In our screening program, we have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Drug Transport and Resistance Mechanisms
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14998323
DOI: 10.1021/jm031011g

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Studies on Pyrrolopyrimidines as Selective Inhibitors of Multidrug-Resistance- Associated Protein in Multidrug ResistancePMID 14998323Read ↗

Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advancesSemantic proximity Read ↗

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)Semantic proximity Read ↗

Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer TreatmentSemantic proximity Read ↗

The Functions and Structure of ABC Transporters: Implications for the Design of New Inhibitors of Pgp and MRP1 to Control Multidrug Resistance (MDR)Semantic proximity Read ↗

Development of heterocyclic derivatives as P-glycoprotein inhibitors against multidrug resistance: pharmacological activities, structure–activity relationship and target (2020–2024)Semantic proximity Read ↗

Role of the MRP1/ABCC1 Multidrug Transporter Protein in CancerSemantic proximity Read ↗

Recent attempts at RNAi‐mediated P‐glycoprotein downregulation for reversal of multidrug resistance in cancerSemantic proximity Read ↗

Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of NeuroblastomaSemantic proximity Read ↗

Synthetic modified pyrrolo[1,4] benzodiazepine molecules demonstrate selective anticancer activity by targeting the human ligase 1 enzyme: An in silico and in vitro mechanistic studySemantic proximity Read ↗

Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer ChemotherapySemantic proximity Read ↗

Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy.Semantic proximity Read ↗

Inhibitors of Multidrug Resistance to Antitumor Agents (MDR)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.